MTOR and hepatocellular carcinoma: The results showed that within this cohort of 15 HCC PDX models, four exhibited sensitivities to the mTOR inhibitor, two were sensitive to vinorelbine, three were sensitive to both vinorelbine and the mTOR inhibitor, and six were resistant to both vinorelbine and the mTOR inhibitor (Table 1).